Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

AIM: To use continuous glucose monitoring (CGM)‐based time‐in‐range (TIR) as a primary efficacy endpoint to compare the second‐generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla‐300) and insulin degludec 100 U/ml (IDeg‐100) in adults with type 1 diabetes (T1D). MATERIALS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Battelino, Tadej, Danne, Thomas, Edelman, Steve V., Choudhary, Pratik, Renard, Eric, Westerbacka, Jukka, Mukherjee, Bhaswati, Pilorget, Valerie, Coudert, Mathieu, Bergenstal, Richard M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100006/
https://www.ncbi.nlm.nih.gov/pubmed/36263928
http://dx.doi.org/10.1111/dom.14898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100006/
https://www.ncbi.nlm.nih.gov/pubmed/36263928
http://dx.doi.org/10.1111/dom.14898

Ejemplares similares